Strides Pharma Divests Majority Stake in Pivot Path for ~Rs 1,000 Mn

Strides Pharma Science has approved the sale of a majority stake in its life sciences consulting subsidiary, Pivot Path, to a consortium led by Ascent Capital. Key Deal Metrics: Transaction Value: ~Rs 1,000 million secondary stake sale to Strides + a ~Rs 500 million primary capital infusion into Pivot Path. Post-Deal Shareholding: Investors (65.05%), ESOP Pool (15%), and Strides (19.95%). Pivot Path will be reclassified from a subsidiary to an associate company. Target Profile: Carved out from Strides' Global Capability Centre (GCC) in May 2026, Pivot Path contributed ~3% (Rs 1,447 million) to Strides' FY26 consolidated turnover. Strategic Impact: This arm's-length transaction unlocks significant value from a non-core business. It equips Pivot Path with dedicated private equity capital and management incentives (via the 15% ESOP) to scale independently. Meanwhile, Strides generates immediate cash flow, optimizes its corporate portfolio, and retains a ~20% stake to capture future financial upside. $STAR